Phase I Data on SAHA, a Histone Deacetylase Inhibitor

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 12 No 1
Volume 12
Issue 1

TARRYTOWN, New York-Aton Pharma, Inc and its collaborators presented phase I data on its oral histone deacetylase inhibitor SAHA (suberoylanilide hydroxamic acid) at the 14th Annual EORTC/NCI/AACR symposium, held in Frankfurt, Germany. The trial of patients with refractory solid tumors, lymphomas, and leukemias, being conducted with researchers at Memorial Sloan-Ket-tering Cancer Center, defined a safe daily oral dosing regimen.

TARRYTOWN, New York—Aton Pharma, Inc and its collaborators presented phase I data on its oral histone deacetylase inhibitor SAHA (suberoylanilide hydroxamic acid) at the 14th Annual EORTC/NCI/AACR symposium, held in Frankfurt, Germany. The trial of patients with refractory solid tumors, lymphomas, and leukemias, being conducted with researchers at Memorial Sloan-Ket-tering Cancer Center, defined a safe daily oral dosing regimen.

Evidence of antitumor activity was also observed. Of the 28 patients with solid tumors, one (larynx cancer) had a partial response, two (renal cell cancer and transitional cell cancer) had reduction in measurable disease, and one (papillary thyroid cancer) had stable disease for more than 2 months.

Articles in this issue
Phase II Trial of Phenoxodiol in Recurrent Ovarian Cancer Is launched
FDA Approves New Taxotere Indication as First-Line Therapy for NSCLC
Most Cancer Pain Is Experienced at the Patient’s Home
HHS Unites Its HIV Advisors
First NCI Health Disparity Grants
Pain Therapy Improves Quality of Life for Caregivers
Inex to Seek FDA Approval for Onco TCS (Liposomal Vincristine)
CD40L-Expressing Dendritic Cells Eliminate Breast Tumors in Mice
Safe Handling Tips for Use of Testosterone Gel
Lumpectomy/Mastectomy Equivalent in Early Breast Cancer
New Agent Tested in Refractory and Relapsed Ovarian Cancer
HIV Testing of Pregnant Women Increases: CDC Report
Targeted Home Nursing Visits Post Breast Surgery Cost-Effective
IRIS Trial Update Confirms Imatinib Advantage in CML
Elderly Vulnerable to Febrile Neutropenia Early in Chemotherapy
Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content
Confirmatory data may support zanidatamab as an advancement in the treatment of HER2-positive advanced gastroesophageal adenocarcinoma.

Zanidatamab Combo Has Meaningful Activity in HER2+ Gastroesophageal Cancer

Russ Conroy
July 5th 2025
Article

Confirmatory data may support zanidatamab as an advancement in the treatment of HER2-positive advanced gastroesophageal adenocarcinoma.

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

As AI revolutionizes cancer care by enhancing diagnosis, treatment, and clinical trial matching, it may lead to improved patient outcomes and streamlined workflows.

Current Use and Future Directions of Artificial Intelligence in Hematology/Oncology

Julie M. Vose, MD, MBA
July 5th 2025
Article

As AI revolutionizes cancer care by enhancing diagnosis, treatment, and clinical trial matching, it may lead to improved patient outcomes and streamlined workflows.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.

Obrixtamig Plus Topotecan Shows Tolerability, Efficacy in Advanced ES-SCLC

Roman Fabbricatore
July 4th 2025
Article

The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.

Experts discussed diagnosing and treating epithelioid sarcoma, emphasizing the importance of clinical history and the role of multiple multidisciplinary clinicians in care.

Diagnosing and Treating Patients With Epithelioid Sarcoma

ONCOLOGY Staff
July 4th 2025
Article

Experts discussed diagnosing and treating epithelioid sarcoma, emphasizing the importance of clinical history and the role of multiple multidisciplinary clinicians in care.